Home company acquires
 

Keywords :   


Tag: company acquires

Tekni-Plex Acquires Indian Closure Liner Company Ghiya Extrusions

2015-02-20 11:31:20| Industrial Newsroom - All News for Today

WAYNE, Pa.  Tekni-Plex is pleased to announce the acquisition of Ghiya Extrusions Private Ltd., a leading supplier of EPE foam closure liners in the domestic India and export markets. Located in Ahmedabad, India, the acquisition expands Tekni's commitment to its existing business in India and to growing its closure...

Tags: company indian closure liner

 

H.B. Fuller Company Acquires Tonsan Adhesive

2015-02-02 06:00:00| Coatings World Breaking News

Tags: company fuller adhesive acquires

 
 

Amcor acquires Chinese flexible packaging company

2014-12-19 06:00:00| Label and Narrow Web Breaking News

"China is one of the most attractive markets for flexible packaging globally, says Ken MacKenzie, Amcor's CEO.

Tags: company chinese flexible packaging

 

Mozido Acquires Majority Ownership In Mobile Commerce Company CorFire

2014-12-19 05:20:00| dairynetwork Home Page

Mozido, a cloud platform mobile payments and retail engagement solutions provider, today announced it has acquired the majority ownership in SK C&C USA dba CorFire, a U.S.-based mobile commerce company previously wholly-owned by South Korean IT services provider SK C&C

Tags: company mobile commerce ownership

 

Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

2014-12-18 13:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Acquisition Expands Mercks Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: company held solid developing

 

Sites : [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] next »